UCB announces Nayzilam (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the US

UCB

19 May 2019 - Nayzilam allows for administration by a non-healthcare professional in patients actively seizing when and where a seizure cluster occurs.

UCB announced today that the U.S. FDA has approved a new drug application for the company’s newest anti-epileptic drug Nayzilam (midazolam) nasal spray, a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older. 

Nayzilam now provides patients and caregivers with the first and only FDA-approved nasal option for treating seizure clusters.

Read UCB press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US